Sousa-Pinto, BLouis, RAnto, JMAmaral, RSá-Sousa, ACzarlewski, WBrussino, LCanonica, GWLoureiro, CCCruz, AAGemicioglu, BHaahtela, TKupczyk, MKvedariene, VLarenas-Linnemann, DEOkamoto, YOllert, MPfaar, OPham-Thi, NPuggioni, FRegateiro, FSRomantowski, JSastre, JScichilone, NTaborda-Barata, LVentura, MTAgache, IBedbrook, ABecker, SBergmann, KCBosnic-Anticevich, SBonini, MBoulet, LPBrusselle, GBuhl, RCecchi, LCharpin, Dde Blay, FDel Giacco, SIvancevich, JCJutel, MKlimek, LKraxner, HKuna, PLaune, DMakela, MMorais-Almeida, MNadif, RNiedoszytko, MPapadopoulos, NGPapi, APatella, VPétré, BYeverino, DRCordeiro, CRRoche, NRouadi, PWSamolinski, BSavouré, MShamji, MHSheikh, AUlrik, CSUsmani, OSValiulis, AYorgancioglu, AZuberbier, TFonseca, JACosta, EMBousquet, J2025-04-102025-04-102531-0437http://hdl.handle.net/20.500.14701/43368Introduction Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting beta 2-agonists (ICS+LABA) in users of the MASK-air((R)) app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods We analysed complete weeks of MASK-air((R)) data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication =80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.EnglishArticle